AI-Based Design Enhances Efficacy and Safety of Immune Cancer Therapies
Galux presented preclinical data at AACR 2026 demonstrating that its AI-designed bispecific antibody significantly enhances tumor-killing efficacy while minimizing off-target toxicity. By leveraging generative protein design, Galux aims to solve ... Read More